Karyopharm planning selinexor submissions in MM

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) reported that selinexor (KPT-330) met the primary endpoint of improving overall response rate (ORR) in the Phase IIb STORM trial to treat penta-refractory multiple myeloma. Based on the data,

Read the full 333 word article

User Sign In